INOVIO Pharmaceuticals Inc. has announced the publication of peer-reviewed data from a retrospective study on their DNA immunotherapy, INO-3107, in The Laryngoscope. The study investigated the long-term clinical and safety response of patients with Recurrent Respiratory Papillomatosis (RRP) treated with INO-3107. Results showed a significant reduction in the number of surgeries required to manage the disease, with the Overall Response Rate improving to 86% by the end of the second year, compared to 72% at the end of the first year. The Complete Response rate increased from 28% in the first year to 50% in the second year. The mean number of surgeries needed dropped from 4.1 per year before treatment to 0.9 by the second year. Partial data extending into the third year continued to show improvement. INO-3107 was well tolerated with no serious adverse events or long-term safety issues identified.